Duration-Dependent Increase of Human Bone Matrix Mineralization in Long-Term Bisphosphonate Users with Atypical Femur Fracture

Delphine Farlay, Sébastien Rizzo, Louis-Georges Ste-Marie, Laëtitia Michou, Suzanne N Morin, Shijing Qiu, Pascale Chavassieux, Roland D Chapurlat, Sudhaker D Rao, Jacques P Brown, Georges Boivin, Delphine Farlay, Sébastien Rizzo, Louis-Georges Ste-Marie, Laëtitia Michou, Suzanne N Morin, Shijing Qiu, Pascale Chavassieux, Roland D Chapurlat, Sudhaker D Rao, Jacques P Brown, Georges Boivin

Abstract

Bisphosphonates (BPs) are the most widely used drugs for the treatment of osteoporosis but prolonged use of BPs might increase the risk of atypical femur fracture (AFF). There are only a few studies that address the bone material quality in patients on long-term BP treatment with or without AFFs. We analyzed 52 trans-iliac bone biopsies from patients on long-term BP therapy with (n = 26) and without (n = 26) AFF. At the microscopic level, the degree of mineralization of bone (DMB) was assessed on whole bone by X-ray digitized microradiography while microhardness by Vickers microindentation, and bone matrix characteristics by Fourier transform infrared microspectroscopy (FTIRM) (mineral/organic ratio, mineral maturity and crystallinity, and collagen maturity) were measured at random focal areas. The AFF patients were treated longer than non-AFF patients (9.7 ± 3.3 years versus 7.9 ± 2.7 years). As expected, bone remodeling was low in both groups, without difference between them. The AFF group had significantly higher DMB in cortical bone (+2.9%, p = .001), which remained so after adjusting for treatment duration (p = .007), and showed a trend in cancellous bone (+1.6%, p = .05). Consistent with higher DMB, heterogeneity index (HI) was lower in the AFF than in the non-AFF group, illustrating lower heterogeneity of mineralization in the AFF group. A significant positive correlation between the duration of treatment and DMB in cortical bone was found in AFF, and not in the non-AFF group. Microhardness and bone matrix characteristics were similar between groups. We conclude that the AFF group had a duration-dependent increase in DMB leading to a significantly higher DMB than the non-AFF. Because BPs have high affinity to bone mineral and lining the walls of the osteocyte lacunae, the accumulation of matrix-bound BPs in AFF could lead to inhibition of the osteocyte cytoskeleton blunting their response to mechanical strains, a hypothesis to be further investigated. © 2021 American Society for Bone and Mineral Research (ASBMR).

Trial registration: ClinicalTrials.gov NCT02155595.

Keywords: ATYPICAL FEMUR FRACTURE; BISPHOSPHONATES; BONE HISTOMORPHOMETRY; BONE MATRIX MINERALIZATION; MICROINDENTATION.

© 2021 American Society for Bone and Mineral Research (ASBMR).

References

    1. Black DM, Abrahamsen B, Bouxsein ML, Einhorn T, Napoli N. Atypical femur fractures: review of epidemiology, relationship to bisphosphonates, prevention, and clinical management. Endocr Rev. 2019;40(2):333-68.
    1. Starr J, Tay YKD, Shane E. Current understanding of epidemiology, pathophysiology, and management of atypical femur fractures. Curr Osteoporos Rep. 2018;16(4):519-29.
    1. Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29(1):1-23.
    1. Shane E, Burr D, Ebeling PR, et al. American Society for Bone and Mineral Research. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25(11):2267-94.
    1. Koch JC. The laws of bone architecture. Am J Anat. 1917;21:177-298.
    1. Adler RA, Fuleihan GE, Bauer DC, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31(1):16-35.
    1. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CYC. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90(3):1294-301.
    1. Armamento-Villareal R, Napoli N, Diemer K, et al. Bone turnover in Bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif Tissue Int. 2009;85:37-44.
    1. Black DM, Geiger EJ, Eastell R, et al. Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. N Engl J Med. 2020;383(8):743-53.
    1. Brown JP. Antiresorptives: safety concerns-clinical perspective. Toxicol Pathol. 2017;45(7):859-63.
    1. Larsen MS, Schmal H. The enigma of atypical femoral fractures: a summary of current knowledge. EFORT Open Rev. 2018;3(9):494-500.
    1. Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375(16):1532-43.
    1. Dell RM, Adams AL, Greene DF, et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res. 2012;27(12):2544-50.
    1. Lo JC, Grimsrud CD, Ott SM, Chandra M, Hui RL, Ettinger B. Atypical femur fracture incidence in women increases with duration of bisphosphonate exposure. Osteoporos Int. 2019;30(12):2515-20.
    1. Schilcher J, Michaëlsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med. 2011;364(18):1728-37.
    1. Ettinger B, Burr DB, Ritchie RO. Proposed pathogenesis for atypical femoral fractures: lessons from materials research. Bone. 2013;55(2):495-500.
    1. Li J, Mashiba T, Burr DB. Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int. 2001;69(5):281-6.
    1. Allen MR. Recent advances in understanding bisphosphonate effects on bone mechanical properties. Curr Osteoporos Rep. 2018;16(2):198-204.
    1. Bala Y, Depalle B, Farlay D, et al. Bone micromechanical properties are compromised during long-term alendronate therapy independently of mineralization. J Bone Miner Res. 2012;27(4):825-34.
    1. Popp KL, Caksa S, Martinez-Betancourt A, et al. Cortical bone material strength index and bone microarchitecture in postmenopausal women with atypical femoral fractures. J Bone Miner Res. 2019;34(1):75-82.
    1. Güerri-Fernández RC, Nogués X, Quesada Gómez JM, et al. Microindentation for in vivo measurement of bone tissue material properties in atypical femoral fracture patients and controls. J Bone Miner Res. 2013;28(1):162-8.
    1. Lloyd AA, Gludovatz B, Riedel C, et al. Atypical fracture with long-term bisphosphonate therapy is associated with altered cortical composition and reduced fracture resistance. Proc Natl Acad Sci U S A. 2017 15;;114(33):8722-7.
    1. Tjhia CK, Odvina CV, Rao DS, Stover SM, Wang X, Fyhrie DP. Mechanical property and tissue mineral density differences among severely suppressed bone turnover (SSBT) patients, osteoporotic patients, and normal subjects. Bone. 2011;49(6):1279-89.
    1. Montagner F, Kaftandjian V, Farlay D, Brau D, Boivin G, Follet H. Validation of a novel microradiography device for characterization of bone mineralization. J Xray Sci Technol. 2015;23(2):201-11.
    1. Boivin G, Bala Y, Doublier A, et al. The role of mineralization and organic matrix in the microhardness of bone tissue from controls and osteoporotic patients. Bone. 2008;43(3):532-8.
    1. Farlay D, Panczer G, Rey C, Delmas PD, Boivin G. Mineral maturity and crystallinity index are distinct characteristics of bone mineral. J Bone Miner Metab. 2010;28(4):433-45.
    1. Farlay D, Duclos M-E, Gineyts E, et al. The ratio 1660/1690 cm(−1) measured by infrared microspectroscopy is not specific of enzymatic collagen cross-links in bone tissue. PLoS One. 2011;6(12):e28736.
    1. Paschalis EP, Verdelis K, Doty SB, Boskey AL, Mendelsohn R, Yamauchi M. Spectroscopic characterization of collagen cross-links in bone. J Bone Miner Res. 2001;16(10):1821-8.
    1. Gardegaront M, Farlay D, Peyruchaud O, Follet H. Automation of the peak fitting method in bone FTIR microspectroscopy spectrum analysis: human and mice bone study. J Spectrosc. 2018. .
    1. Lu Y, Fuerst T, Hui S, Genant HK. Standardization of bone mineral density at femoral neck, trochanter and Ward's triangle. Osteoporos Int. 2001;12(6):438-44.
    1. Hui SL, Gao S, Zhou XH, et al. Universal standardization of bone density measurements: a method with optimal properties for calibration among several instruments. J Bone Miner Res. 1997;12(9):1463-70.
    1. Qiu S, Divine GW, Palnitkar S, et al. Bone structure and turnover status in postmenopausal women with atypical femur fracture after prolonged bisphosphonate therapy. Calcif Tissue Int. 2017;100(3):235-43.
    1. Dempster DW, Compston JE, Drezner MK, et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 2013;28(1):2-17.
    1. Paschalis EP, DiCarlo E, Betts F, Sherman P, Mendelsohn R, Boskey AL. FTIR microspectroscopic analysis of human osteonal bone. Calcif Tissue Int. 1996;59(6):480-7.
    1. Brown JP, Morin S, Leslie W, et al. Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician. 2014;60(4):324-33.
    1. Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513-23.
    1. Chapurlat RD. Odanacatib: a review of its potential in the management of osteoporosis in postmenopausal women. Ther Adv Musculoskelet Dis. 2015;7(3):103-9.
    1. Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone. 2000;27(5):687-94.
    1. Bala Y, Farlay D, Chapurlat RD, Boivin G. Modifications of bone material properties in postmenopausal osteoporotic women long-term treated with alendronate. Eur J Endocrinol. 2011;165(4):647-55.
    1. Dempster DW, Brown JP, Fahrleitner-Pammer A, et al. Effects of long-term denosumab on bone histomorphometry and mineralization in women with postmenopausal osteoporosis. J Clin Endocrinol Metab. 2018;103(7):2498-509.
    1. Gedmintas L, Solomon DH, Kim SC. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res. 2013;28(8):1729-37.
    1. Farlay D, Bala Y, Rizzo S, et al. Bone remodeling and bone matrix quality before and after menopause in healthy women. Bone. 2019;128:115030.
    1. Griffin L, Nelson S, Qiu S, Warner E, Honasoge M, Rao S. Material properties of trans-iliac bone biopsies, as assessed by nanoindentation (NI), in patients with and without atypical femur fractures (AFF) on long-term bisphosphonate (BP) therapy for low bone density: a prospective nested case-controlled study. J Bone Miner Res. 2019;32(Suppl 1):381. Available from: .
    1. Allen MR, Burr DB. Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don't know. Bone. 2011;49(1):56-65.
    1. Chapurlat RD, Arlot M, Burt-Pichat B, et al. Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J Bone Miner Res. 2007;22(10):1502-9.
    1. Morin SN, Wall M, Belzile EL, et al. Assessment of femur geometrical parameters using EOS™ imaging technology in patients with atypical femur fractures; preliminary results. Bone. 2016;83:184-9.
    1. Poundarik AA, Wu P-C, Evis Z, et al. A direct role of collagen glycation in bone fracture. J Mech Behav Biomed Mater. 2015;52:120-30.
    1. Viguet-Carrin S, Garnero P, Delmas PD. The role of collagen in bone strength. Osteoporos Int. 2006;17(3):319-36.
    1. Schaffler MB, Cheung W-Y, Majeska R, Kennedy O. Osteocytes: master orchestrators of bone. Calcif Tissue Int. 2014;94(1):5-24.
    1. Hemmatian H, Bakker AD, Klein-Nulend J, van Lenthe GH. Aging, osteocytes, and mechanotransduction. Curr Osteoporos Rep. 2017;15(5):401-11.
    1. Vrahnas C, Blank M, Dite TA, et al. Increased autophagy in EphrinB2-deficient osteocytes is associated with elevated secondary mineralization and brittle bone. Nat Commun. 2019;10(1):3436.
    1. Blank M, Sims NA. Cellular processes by which osteoblasts and osteocytes control bone mineral deposition and maturation revealed by stage-specific EphrinB2 knockdown. Curr Osteoporos Rep. 2019;17(5):270-80.
    1. Kazmers NH, Ma SA, Yoshida T, Stern PH. Rho GTPase signaling and PTH 3-34, but not PTH 1-34, maintain the actin cytoskeleton and antagonize bisphosphonate effects in mouse osteoblastic MC3T3-E1 cells. Bone. 2009;45(1):52-60.
    1. Nollet M, Santucci-Darmanin S, Breuil V, et al. Autophagy in osteoblasts is involved in mineralization and bone homeostasis. Autophagy. 2014;10(11):1965-77.
    1. Khandelwal VKM, Mitrofan LM, Hyttinen JMT, et al. Oxidative stress plays an important role in zoledronic acid-induced autophagy. Physiol Res. 2014;63(Suppl 4):S601-12.
    1. Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006;38(5):617-27.
    1. Roelofs AJ, Coxon FP, Ebetino FH, et al. Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J Bone Miner Res. 2010;25(3):606-16.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe